Oct 23 (Reuters) - Amgen Inc :Phase 3 A.R.R.O.W. study of once-weekly KYPROLIS(carfilzomib) regimen meets primary endpoint of progression-free survival in relapsed and refractory multiple myeloma patients.Amgen Inc - overall safety profile of once-weekly KYPROLIS regimen was comparable to that of twice-weekly regimen.
Oct 23 (Reuters) - Evoke Pharma Inc ::Evoke Pharma announces positive topline results from comparative exposure pharmacokinetic study for gimoti™.Evoke Pharma- co will submit a 505(b)(2) NDA with a selected gimoti dose to the U.S. FDA in Q1 of 2018.Evoke Pharma Inc- relative to safety, all gimoti doses were well‑tolerated.
Oct 23 (Reuters) - Aphria Inc :Aphria - executives met with TSX representatives on Oct 20 to discuss exchange's guidance on Section 306, Section 325, Part VII of TSX Company Manual.Aphria Inc - has not received notice from TSX of a continued listing review.
Oct 23 (Reuters) - CHO pharma Inc <6586.TWO> ::Says it appoints Tzen Wen Chen as new chairman and general manager of the company, to replace Lan-Bo Chen, effective Oct. 23 .
Oct 23 (Reuters) - Fuso Pharmaceutical Industries Ltd <4538.T>:Says it will sell Aichi-based property on Oct. 31, and capital gains is 567 million yen .